Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

NCT06065371 Phase 1 RECRUITING

This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.

Details

Lead sponsor	Henry Ford Health System
Phase	Phase 1
Status	RECRUITING
Enrolment	20
Start date	2024-11-20
Completion	2027-05

Conditions

• Gastrointestinal Cancer

Interventions

• Capecitabine
• Sacituzumab govetican

Primary outcomes

• Primary Endpoint — 18 months
  Recommended phase 2 dose (RP2D)

Countries

United States